Search results
Results from the WOW.Com Content Network
Lumpectomy (sometimes known as a tylectomy, partial mastectomy, breast segmental resection or breast wide local excision) is a surgical removal of a discrete portion or "lump" of breast tissue, usually in the treatment of a malignant tumor or breast cancer. [1]
Sep. 2—MITCHELL, S.D. — It was this past May when Sister Marita Pfau first noticed an unusual indentation on her breast during a self-exam. "I happen to notice that in the mirror, whether I ...
Breast-conserving surgery may also be used in cases of biopsy-proven invasive breast cancer or biopsy-proven ductal carcinoma in situ. In the assessment of the tumor, the surgeon should assess the ability to resect the tumor with clear margins while providing a cosmetic result that is acceptable to the patient.
The researchers discovered that women who underwent a lumpectomy (where the tumor and surrounding tissue is removed but the breast is largely left intact) or a mastectomy (where one breast is ...
Management options for patients with invasive breast carcinomas include surgery, radiotherapy, and systemic adjuvant medical therapy. Surgical treatment ranges from radical mastectomy to breast conserving procedures such as lumpectomy. Patients at risk for local recurrence of disease may be offered radiotherapy.
The 2015 update of guidelines of the Association of Gynecological Oncology (AGO), an autonomous community of the German Society of Gynecology and Obstetrics (DGGG) and the German Cancer Society includes TARGIT IORT during lumpectomy as a recommended option for women with a T1, Grade 1 or 2, ER positive breast cancer. [5]
The efficacy and safety of pegulicianine were evaluated in a multicenter, intra-participant controlled clinical trial (NCT03686215) of participants with breast cancer undergoing lumpectomy surgery. [3] A total of 357 participants underwent image-guided surgery with the Lumicell DVS following standard of care lumpectomy. [3]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.